Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biotechnology company focused on cell therapy and immunotherapies for cancer and other incurable diseases. Its news flow is heavily driven by clinical data updates, regulatory interactions, and collaboration milestones related to its lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), for relapsed or refractory multiple myeloma.
Investors and observers following Arcellx news can expect regular announcements on the company’s pivotal Phase 2 iMMagine-1 study and its global Phase 3 iMMagine-3 trial. Recent releases have highlighted high overall response rates, deep responses, and high minimal residual disease (MRD) negativity in heavily pretreated multiple myeloma patients, along with detailed safety observations such as the absence of specific delayed neurotoxicities in reported data cuts.
Arcellx also issues news on key regulatory milestones, including a pre-BLA meeting with the U.S. Food and Drug Administration for anito-cel and the addition of MRD negativity as a dual primary endpoint in iMMagine-3. Updates on FDA designations for anito-cel, such as Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy status, are part of this regulatory-focused news stream.
Beyond multiple myeloma, Arcellx news covers pipeline expansion, such as FDA clearance of an IND for ACLX-004 targeting CD33 and CD123 using the ARC-SparX platform, as well as financial results, cash runway commentary, and collaboration developments with Kite, a Gilead Company. Coverage also includes participation in major scientific meetings like EHA and ASH, where Arcellx presents clinical data and scientific findings. For readers tracking ACLX, this news page provides a centralized view of clinical, regulatory, financial, and corporate developments that shape the company’s progress in cell therapy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm specializing in immunotherapies for cancer and other severe diseases, will participate in the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. This session will be a fireside chat featuring company management.
A live webcast will be available on Arcellx's website, and a replay will be accessible for 30 days post-event. Arcellx focuses on innovative cell therapies, including its lead candidate, CART-ddBCMA, targeting relapsed or refractory multiple myeloma, currently in a Phase 2 trial. The FDA has granted it several designations, including Fast Track and Orphan Drug.
Arcellx, Inc. (NASDAQ: ACLX) reported significant business highlights and financial results for Q4 and the year ended December 31, 2022. The company signed a strategic collaboration with Kite to co-develop CART-ddBCMA for multiple myeloma, receiving $225 million upfront and a $100 million equity investment. In clinical trials, CART-ddBCMA showed a 100% overall response rate in a Phase 1 trial. However, R&D expenses surged to $149.6 million for 2022 due to non-cash expenses and increased headcount. Arcellx ended 2022 with $254.8 million in cash, positioning it well for further pipeline development.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on innovative immunotherapies for cancer, announced participation in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 1:00 p.m. ET. A live webcast will be available on Arcellx's website in the Investors section, with a replay accessible for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma and is also developing the dosable CAR-T therapy, ARC-SparX. The company holds multiple FDA designations for its therapies, reinforcing its commitment to advancing cell therapy.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm focused on innovative immunotherapies for cancer, announced its participation in two upcoming investor conferences. The Guggenheim Oncology Conference will feature a fireside chat on February 9, 2023, at 11:20 a.m. ET, while the SVB Securities Global Biopharma Conference will be held virtually on February 16, 2023, at 3:00 p.m. ET. Live webcasts will be available on Arcellx's website with replays archived for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, in pivotal trials for multiple myeloma, supported by several FDA designations.